Lantheus (NASDAQ:LNTH) Stock Price Up 4.5% on Analyst Upgrade

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price traded up 4.5% during trading on Thursday after B. Riley raised their price target on the stock from $95.00 to $99.00. B. Riley currently has a buy rating on the stock. Lantheus traded as high as $64.22 and last traded at $64.22. 151,982 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 1,046,329 shares. The stock had previously closed at $61.48.

Several other analysts have also recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a research report on Monday, February 26th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.71.

Insiders Place Their Bets

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 94,545 shares of company stock valued at $6,169,936. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Silverberg Bernstein Capital Management LLC purchased a new position in Lantheus in the 4th quarter worth about $1,385,000. Natixis Advisors L.P. boosted its holdings in Lantheus by 172.8% in the third quarter. Natixis Advisors L.P. now owns 52,530 shares of the medical equipment provider’s stock worth $3,649,000 after purchasing an additional 33,273 shares during the last quarter. American Century Companies Inc. grew its position in Lantheus by 41.9% in the 3rd quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after purchasing an additional 384,093 shares during the period. Boston Partners raised its stake in Lantheus by 15.2% during the 3rd quarter. Boston Partners now owns 512,930 shares of the medical equipment provider’s stock valued at $35,326,000 after buying an additional 67,729 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in shares of Lantheus by 60.5% during the 3rd quarter. Lazard Asset Management LLC now owns 336,946 shares of the medical equipment provider’s stock valued at $23,410,000 after buying an additional 126,947 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The stock has a market capitalization of $4.37 billion, a P/E ratio of 13.75 and a beta of 0.53. The firm has a fifty day moving average price of $60.81 and a two-hundred day moving average price of $62.97.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. The business had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. As a group, analysts expect that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.